"Mr Polizzi successfully led the process for several dozen U.S. and International Pharma strategic license and acquisitions, from identification of target companies, negotiations, and due diligence through execution. Evaluated hundreds of prospective M&A, licensing, or acquisition transactions throughout his career."
This is what is immediately relevant for us now. Evaluating hundreds, and proceeding with dozens, of licenses or acquisitions, is a lot. He will know his counterparts in the other majors, what they are looking for, the basis for their assessments, what they will need to complete a deal, and the outer limits of their negotiating positions.
Ann: Paradigm Appoints Experienced US-Based CEO, page-13
-
- There are more pages in this discussion • 70 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
0.035(12.7%) |
Mkt cap ! $108.4M | |||
| Open | High | Low | Value | Volume |
| 27.5¢ | 31.0¢ | 27.5¢ | $108.9K | 371.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 17420 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |